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Table 2
Before
PMBV
After
PMBV
3st
month
1 st
year p⃰ P1** P2** P3** P4**
Systolic
velocity
(cm/sn)
12
(9-17)
15
(11-17)
13
(10-16)
12
(10-15)
<0,001 <0,001 <0,001 AD AD
Early
diastolic
velocity
(cm/s)
10
(8-14)
13
(10-16)
11
(8-16)
11
(8-15)
<0,001 <0,001 <0,001 AD AD
late
diastolic
velocity
(cm/s)
12
(8-16)
11
(8-16)
11
(8-15)
11
(8-15)
<0,001 <0,001 AD AD AD
Comparison of before and after PMBV (at 48 hours, 3 months and 1 year) Pulsed tissue
Doppler imaging variables measured by Transthoracic Echocardiography
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Background: Aortic stenosis (AS) leads to the remodeling of left heart. Longstanding
afterload increase due to AS results in compensatory concentric left ventricular (LV)
hypertrophy and LV diastolic dysfunction which indirectly impair left atrial (LA)
functions. The aim of this study was to evaluate the short term effects of transcatheter
aortic valve implantation (TAVI) on LV diastolic and left atrial appendage (LAA)
function.
Methods: Ninety-one patients with severe AS were examined during their hospital
stay by echocardiography before and 3,4 1,2 days after TAVI. Transmitral ﬂow was
acquired to obtain peak early (E) and late (A) atrial ﬂow velocities. We used the
average peak early diastolic (E’) velocity obtained from the septal side of the mitral
annulus in the four chamber view. 35 of the 91 patients were evaluated with trans-
esophageal echocardiography (TEE) and LAA anterograde ﬂow velocities were
measured before and within minutes after TAVI in catheterization laboratory.
Results: The study consisted of a total of 91 consecutive patients in whom TAVI was
performed. The mean age was 78.37.43 years. Of the 91 consecutive study patients,
63 were female (69%). The mean body mass index (BMI) was 28.38.6 kg/m2. The
calculated mean logistic EuroSCORE was 22.316.2 and STS score 7.575.3.
Baseline examination of patients revealed mean ejection fraction as 53.8%14.4.
SURTAVI risk score was low in 9 patients, medium in 29 patients and high in 48
patients. Before TAVI, mean mitral E/A velocities was 1.240.68 and after TAVI
before hospital discharge mean mitral E/A velocities was 1.190.67 and this ﬁnding
was statistically signiﬁcant (p¼0.001). There was a signiﬁcant reduction in septal
early diastolic velocities after TAVI compared to baseline values (0.0530.11 vs
0.0520.13, p¼0.001). LAA anterograde ﬂow velocities assessed by TEE in 35 of 91
patients changed signiﬁcantly within minutes after TAVI (32.4510.7 cm/s vs
47.612.61 cm/s p<0.001).
Conclusions: In this study, LAA anterograde ﬂow velocities improved within minutes
of TAVI suggest the early improvement of LAA and LA functions. Also, we deter-
mined the amelioration of LV diastolic functions within days after TAVI. These
ﬁndings indicate that, after TAVI, there is a recovery of LV diastolic and LA functions
and this recovery commences immediately.R
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Background: In the PROTECT AF trial, left atrial appendage (LAA) occlusion with
the Watchman device has been proven to be non-inferior to Warfarin in preventing
ischemic stroke in patients with atrial ﬁbrillation (AF) and risk of thromboembolicJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAevents and to be superior in preventing hemorrhagic stroke. The data suggest that
LAA occlusion is especially helpful in AF patients with both a high risk for throm-
boembolic events and for bleeding events with contraindications for oral anti-
coagulation. However in the PROTECT AF trial, the postimplant anticoagulation
protocol was aggressive: all patients get Warfarin combined with ASS for 45 days. At
45 days follow-up, patients were put on ASS plus Clopidogrel until completion of 6
months follow-up. Afterwards a lifelong ASS therapy was recommended. Patients
with contraindications for oral anticoagulation were excluded from the PROTECT AF
trial. For this study the postimplant anticoagulation was attenuated in such way that
patients received ASS lifelong and LMWH for 2 months.
Aim: It was the aim of this analysis to investigate whether an attenuated postimplant
anticoagulation regime is safe in AF patients with high risk for thromboembolic and
hemorrhagic events undergoing LAA occlusion with the Watchman device.
Methods: Patients with chronic paroxysmal or persistent AF and a CHA2DS2-VASc
score (CVS) 3 and a HAS-BLED score (HBS) 3 were eligible for this study. All
patients received 100mg ASS lifelong and bodyweight adapted LMWH once a day for
2 months. Follow-up visits at 2 and 6 months included TEE.
Results: 69 patients were included (mean age: 74+7y; 46 male), all of them had
undergone 2 months and 66/69 6 months follow-up visit so far. The mean CVS was
4.91.3, the mean CHADS2-Score was 3,20,9, the mean HBS was 4.31.0. 36
patients had history of ischemic strokes and 57 patients of major bleeding events.
LAA occlusion was feasible in 68/69 patients. Periprocedural complications were
a stroke without residual neurological deﬁcit in 1 patient, a mild pericardial effusion
not requiring treatment in 3 patients, and groin hematoma in 6 pat.
At 2 months follow-up, the LAA was completely sealed (leakage 3 mm) in all
patients. One Patient showed a ball-shaped thrombus inside the LAA, LMWH was
discontinued in all patients than this one. No stroke or TIA had occurred. Neurological
examination did not reveal any new abnormal ﬁndings. One patient died from
endocarditis, one patient from intestinal ischemia.
At 6 months, 1 patient had experienced a TIA No other patient had any sign of
stroke or peripheral embolism. One patient died from noncardiac reason. So, the
incidence of TIA, stroke or peripheral embolism during the ﬁrst 6 months post
implantation was very low (2/68).
Conclusion: These results suggest that in AF patients with high risk for thrombo-
embolic and bleeding events implantation of the Watchman LAA occlusion device can
be performed safely with an attenuated postimplant anticoag. protocol.Hypertension
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Introduction: Renal denervation is a new promising treatment option which is per-
formed in patients with resistant hypertension deﬁned as blood pressure that remains
above goal despite lifestyle measures and concurrent use of 3 antihypertensive agents
of different classes, prescribed at optimal doses, including a diuretic. Overall,
observational studies and clinical trials suggest that 8%-30% of treated hypertension
patients have resistant hypertension. Here, we report outcomes of the largest series of
renal denervation in Turkey.
Method: 29 patients with resistant hypertension who had undergone renal denervation
procedure were included in our study. Average age of patients were 51.78.3, systolic
and diastolic blood pressures were 177.316.8 and 97.512 mmHg, respectively.
Under local anesthesia, a 6 French introducer sheath was inserted into the right femoral
artery using the standard percutaneous technique. A heparin bolus was then adminis-
tered for anticoagulation. A 6 French double-curve RDC or IMA guiding catheter using
no-touch technique was used for cannulation of ostiums of renal arteries. Nitroglycerin
was directly injected into the arteries to avoid spasm. Then, a specially designed and
commercially available radiofrequency ablation catheter (Symplicity, Medtronic) was
positioned a little bit proximal to the bifurcation of the main renal arteries under
ﬂuoroscopy. Ablation was initiated according to a pre-speciﬁed protocol lasting up to
120 seconds and of 8 watts or less. Midazolam, morphin, fentanyl or pethidin HCL
infusion was used as the sedative or analgesics needed.
Results: Procedure times were 40-45 minutes depending on the length of renal
arteries. During procedures, renal artery spasm developed in 5 patients. It resolved in 4
patients after a bolus of nitroglycerin. But, in one patient multiple spasms resistant to
nitroglycerin and compromising blood ﬂow developed. In 1 patient symptomatic
hypotension was seen. No any other local or systemic complication observed in the
rest. Blood pressures were measured before and after procedures and also in 1, 3, 6, 9
and 12 months after procedures. An average systolic and diastolic blood pressure
reduction of 245 mmHg and 134 mmHg at 12 months were observed respectively.
Discussion: In spite of hesitation in our country, our ﬁndings suggest that catheter-
based renal denervation is an attractive, safe and effective treatment option in patients
with resistant hypertension.LS C29
